Efficacy and Safety of a New Compression System URGO BD001 in the Treatment of VLU (FREEDOM)

Venous Leg Ulcer Clinical Trial

— FREEDOM  

Official title:

Evaluation of the Efficacy and Safety of a New Compression System URGO BD001 in the Treatment of Venous or Mixed Predominantly Venous Leg Ulcers

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04613687
• Other study ID #: FI-19-09-BD001
• Status: Not yet recruiting
• Phase: N/A
• Start date: October 30, 2020
• Est. completion date: September 30, 2021

Study information

• Verified date: October 2020
• Source: Laboratoires URGO
• Contact: Batot Géraldine, PhD
• Phone: +33 3 80 44 28 46
• Email: g.batot[@]fr.urgo.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of this study is to evaluate the therapeutic efficacy and the safety of the new compression system URGO BD001 in the management of venous or mixed predominantly venous leg ulcers. The therapeutic efficacy will be the reduction in wound surface area during a six weeks study treatment period.

Description:

The compression bandage URGO BD001 is indicated for the management of venous leg ulcers with ABPI (Ankle Brachial Pressure Index) ≥ 0.8, venous oedema and lymphedema justifying strong compression.

The pressure applied with the compression system URGO BD001 help to improve venous return and to reduce venous oedema. The expected clinical benefits from the compression system URGO BD001 in patient with a VLU are to increase healing rate and time to healing, and to improve patient quality of life.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 52
• Est. completion date: September 30, 2021
• Est. primary completion date: September 30, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patient affected by VLU or mixed ulcer of predominantly venous origin (ankle brachial pressure index (ABPI) = 0.8 and = 1.3),

• Wound in granulation phase (granulation tissue =50%),

• Wound at least 3 cm away from any edge of another wound,

• VLU between 2 and 20 cm2 in surface area,

• VLU duration between 1 to 24 months.

Exclusion Criteria:

• Patient under guardianship or protection of vulnerable adult,

• Patient with known allergy to any components of the tested compression system,

• Patient with a severe illness that might lead to premature discontinuation of the trial before the end of treatment period,

• Patient with progressive neoplastic lesions treated by radiotherapy, chemotherapy, hormone therapy or immune suppressor,

• Patient with non-controlled systemic infection by a suitable antibiotic therapy,

• Patient who had a deep vein thrombosis within 3 months prior to the inclusion,

• Patient with a lymphedema due to lymphatic obstruction,

• Diabetic patient with advanced diagnosed microangiopathy,

• Bedridden patient, or those spending less than one hour per day on their feet,

• Wound covered partially or totally with necrotic tissue,

• Clinically infected wound,

• Wound requiring surgical treatment or for which a surgery is scheduled during the study period,

• Cancerous lesions.

Related Conditions & MeSH terms

• Leg Ulcer
• Varicose Ulcer
• Venous Leg Ulcer

Intervention

Device:
• Compression bandage
Compression bandage URGO BD001 for the management of venous leg ulcers with ABPI (Ankle Brachial Pressure Index) = 0.8, venous

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Laboratoires URGO

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Relative reduction in wound surface area (percent)	Evolution between D0 and the 6 weeks treatment period with the URGO BD001 compression system: Relative reduction in wound surface area (%) = [(SW6 - SD0)/SD0] × 100 SD0: Wound surface area at D0 SW6: Wound surface area at Week 6	6 weeks
Secondary	Complete ulcer closure:	The percent (%) of patients with complete ulcer closure (100% re-epithelialization) after 6 weeks or at the latest treatment period	6 weeks or last assessment
Secondary	Venous oedema	Oedema reduction from baseline (D0) and last assessment by measuring the limb circumference (in cm), using a tape: Ankle circumference at the reference point B (smallest perimeter of the leg, 3 cm above medial malleolus,; Calf circumference at the reference point C (maximum perimeter of the calf).	6 weeks or last assessment
Secondary	Patient quality of Life (EuroQoL 5D-5L)	EuroQoL 5D-5L between baseline and at last visit. The questionnaire essentially consists of a descriptive system including 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression, and a visual analogue scale (EQ VAS) from "the worst health you can imagine" (0) to "the best health you can imagine" (100).	6 weeks or last assessment
Secondary	Evolution of the periwound skin	Evolution of the peri-wound skin at each visit according to the following parameters: Healthy; Altered: Erythematous and/or squamous (irritated dermatitis/eczema), maceration, other	6 weeks or last assessment
Secondary	Safety analysis	Nature and number of adverse event related to the use of the testing compression system (serious/ non-serious)	6 weeks or last assessment